X4 Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of X4 Pharmaceuticals generated cash of -$96,512,000, which is less than the previous year. Cash used in financing activities reached the amount of $88,516,000 last year. Net change in cash is therefore -$22,780,000.
Cash Flow
| 2015 | -10.81M | -247K | 11.50M |
|---|---|---|---|
| 2016 | -21.63M | -138K | 18.14M |
| 2017 | -27.87M | 34K | 101.26M |
| 2018 | -40.90M | -34K | -4.53M |
| 2019 | -48.05M | 27.23M | 140.66M |
| 2020 | -58.81M | -1.36M | 12.39M |
| 2021 | -70.90M | -615K | 74.24M |
| 2022 | -77.10M | -103K | 117.23M |
| 2023 | -96.51M | -14.88M | 88.51M |
XFOR Cash Flow Statement (2015 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 123.02M | 83.10M | 80.70M | 128.08M | 8.49M | 77.14M | 3.03M | 6.75M | 6.43M |
Operating activities | |||||||||
Net income | -101.16M | -93.86M | -88.69M | -62.13M | -52.80M | -43.02M | -33.87M | -22.97M | -13.21M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 419K | 513K | 499K | 351K | 103K | 155K | 195K | 285K | 389K |
Stock-based compensation expense | 8.68M | 5.19M | 6.18M | 5.42M | 2.05M | 0 | 906K | 644K | 126K |
| Deferred income tax benefit | 8.68M | 5.19M | 6.18M | 5.42M | 2.05M | 0 | 906K | 644K | 126K |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | 0 | -610K | 0 | 0 | 0 | -1.37M | -64K | 152K | -56K |
Inventories | 0 | 610K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 1.23M | 3.42M | 1.16M | 1.03M | -2.75M | -1.33M | 182K | 1.26M | 77K |
Cash generated by operating activities | -96.51M | -77.10M | -70.90M | -58.81M | -48.05M | -40.90M | -27.87M | -21.63M | -10.81M |
Investing activities | |||||||||
Purchases Of Investments | -16.82M | -4.80M | 0 | 0 | 0 | 0 | 0 | -65K | -77K |
Investments In Property Plant And Equipment | -60K | -103K | -615K | -1.36M | -174K | -34K | -42K | -73K | -170K |
Acquisitions Net | 0 | 0 | 0 | 0 | 26.40M | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -14.88M | -103K | -615K | -1.36M | 27.23M | -34K | 34K | -138K | -247K |
Financing activities | |||||||||
Common Stock Issued | 59.99M | 122.63M | 75.98M | -277K | 139.38M | 4.46M | 66M | 5.5M | 7.01M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | -2M | -277K | 0 | -1.12M | -197K | -87K | -12K |
Repayments of term debt | 20.43M | -795K | 0 | -12.38M | 481K | -4.66M | 3.27M | -250K | 4.50M |
Cash used in financing activities | 88.51M | 117.23M | 74.24M | 12.39M | 140.66M | -4.53M | 101.26M | 18.14M | 11.50M |
Net Change In Cash | -22.78M | 39.92M | 2.40M | -47.38M | 119.58M | -45.75M | 73.75M | -3.72M | 320K |
Cash at end of period | 100.24M | 123.02M | 83.10M | 80.70M | 128.08M | 31.39M | 76.79M | 3.03M | 6.75M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |